Kamil Safiejko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamil Safiejko has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Lukasz Szarpak
Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland
10 shared publications Jacek Dadan
Department of General and Endocrinological Surgery, Medical University of Bialystok, Poland
8 shared publications- Marcin Juchimiuk
Department of Oncological Surgery with Specialized Cancer Treatment Units, Maria Sklodowska-Curie Oncology Center, 15-027 Bialystok, Poland
8 shared publications - Michal Pruc
Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland
8 shared publications - Barbara Mroczko
Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
6 shared publications - Monika Zajkowska
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
6 shared publications
Latest Publications
- Open Access
Diagnostic Potential of Circulating CXCL13, CXCL14, and CXCL16 in Colorectal Cancer: A Preliminary Case–Control Study
Introduction: Epidemiological trends indicate that the global colorectal cancer (CRC) mortality will surpass 2.2 million deaths annually by the year 2050; therefore, the identification of novel circulating indicators that may support CRC diagnosis remains an important area of research. Objectives: The diagnostic relevance of circulating chemokines in CRC remains insufficiently understood. This study aimed to evaluate the diagnostic potential of selected serum C-X-C motif chemokines, CXCL13, CXCL14, and CXCL16, and to compare their diagnostic utility with CEA. Patients and Methods: This study included 62 individuals: 42 patients with CRC and 20 healthy volunteers. Serum chemokines levels were measured using a multiplex bead-based immunoassay (Luminex), and CEA levels via chemiluminescent microparticle immunoassay (CMIA). Results: Significant differences between patients with CRC and healthy controls were observed for serum CXCL13 concentrations. Spearman’s analysis revealed a significant negative correlation between CXCL13 and CXCL14. CXCL14 showed the highest diagnostic sensitivity among the chemokines, similar to CEA, while combining CXCL13 or CXCL14 with CEA further increased sensitivity. CXCL13 showed the highest positive predictive value (PPV) among all tested proteins, while its negative predictive value (NPV) and diagnostic accuracy (ACC) exceeded those of CXCL14 and CXCL16. CXCL13 demonstrated the highest AUC among the investigated chemokines and remained independently associated with CRC status in multivariable analysis. CXCL13 combined with CEA yielded the numerically highest overall AUC, although the improvement over CEA alone was not statistically significant. Conclusions: CXCL13 serves as a valuable complementary biomarker, providing crucial additive insights that might augment diagnostic frameworks of patients with CRC. These findings support further evaluation of chemokines as potential adjuncts to established diagnostic biomarkers in larger, independent screening-like study cohorts.
Open AccessDiagnostic Potential of Circulating CXCL13, CXCL14, and CXCL16 in Colorectal Cancer: A Preliminary Case–Control Study
Introduction: Epidemiological trends indicate that the global colorectal cancer (CRC) mortality will surpass 2.2 million deaths annually by the year 2050; therefore, the identification of novel circulating indicators that may support CRC diagnosis remains an important area of research. Objectives: The diagnostic relevance of circulating chemokines in CRC remains insufficiently understood. This study aimed to evaluate the diagnostic potential of selected serum C-X-C motif chemokines, CXCL13, CXCL14, and CXCL16, and to compare their diagnostic utility with CEA. Patients and Methods: This study included 62 individuals: 42 patients with CRC and 20 healthy volunteers. Serum chemokines levels were measured using a multiplex bead-based immunoassay (Luminex), and CEA levels via chemiluminescent microparticle immunoassay (CMIA). Results: Significant differences between patients with CRC and healthy controls were observed for serum CXCL13 concentrations. Spearman’s analysis revealed a significant negative correlation between CXCL13 and CXCL14. CXCL14 showed the highest diagnostic sensitivity among the chemokines, similar to CEA, while combining CXCL13 or CXCL14 with CEA further increased sensitivity. CXCL13 showed the highest positive predictive value (PPV) among all tested proteins, while its negative predictive value (NPV) and diagnostic accuracy (ACC) exceeded those of CXCL14 and CXCL16. CXCL13 demonstrated the highest AUC among the investigated chemokines and remained independently associated with CRC status in multivariable analysis. CXCL13 combined with CEA yielded the numerically highest overall AUC, although the improvement over CEA alone was not statistically significant. Conclusions: CXCL13 serves as a valuable complementary biomarker, providing crucial additive insights that might augment diagnostic frameworks of patients with CRC. These findings support further evaluation of chemokines as potential adjuncts to established diagnostic biomarkers in larger, independent screening-like study cohorts.
- Open Access
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8077
Immunometabolic Biomarkers in Colorectal Cancer: An Exploratory Diagnostic Evaluation of PBEF/NAMPT, Chemerin, and Osteopontin
Immunometabolic dysregulation plays a pivotal role in colorectal cancer (CRC) development and progression. Among the molecules linking inflammation, metabolism, and tumorigenesis, pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase (PBEF/NAMPT), chemerin, and osteopontin (OPN) have emerged as promising circulating biomarkers. This single-center study evaluated their diagnostic performance in patients with colorectal cancer and compared their utility with established tumor markers. Serum concentrations of PBEF/NAMPT, chemerin, and OPN were determined using a magnetic bead-based multiplex immunoassay (Luminex technology), whereas carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured by chemiluminescent microparticle immunoassay (CMIA). The study included 76 patients with colorectal cancer and 38 healthy, colonoscopy-negative controls. Differences between groups were assessed using the Mann–Whitney U, Kruskal–Wallis and post hoc tests, and diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Serum concentrations of PBEF/NAMPT and OPN were significantly higher in patients with CRC than in healthy controls, whereas chemerin did not differ significantly between groups. Among the investigated immunometabolic biomarkers, OPN demonstrated the highest diagnostic accuracy (AUC = 0.747), followed by PBEF/NAMPT (AUC = 0.624), whereas chemerin showed no significant diagnostic value (AUC = 0.559). Combining immunometabolic biomarkers with CEA yielded numerically higher AUC values than CEA alone, with the OPN + CEA panel reaching the highest diagnostic accuracy (AUC = 0.910), followed by the PBEF/NAMPT + CEA combination (AUC = 0.875); however, these increases did not reach statistical significance when formally compared with CEA alone. Among the evaluated immunometabolic biomarkers, OPN demonstrated the greatest diagnostic potential for colorectal cancer, and its combination with CEA warrants further investigation, although these findings should be considered exploratory given the limited sample size and the absence of external validation. Larger, multicenter studies using clinically relevant comparator groups are needed to establish the clinical utility of such multimarker strategies for the non-invasive diagnosis of CRC.
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8077
Open AccessImmunometabolic Biomarkers in Colorectal Cancer: An Exploratory Diagnostic Evaluation of PBEF/NAMPT, Chemerin, and Osteopontin
Immunometabolic dysregulation plays a pivotal role in colorectal cancer (CRC) development and progression. Among the molecules linking inflammation, metabolism, and tumorigenesis, pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase (PBEF/NAMPT), chemerin, and osteopontin (OPN) have emerged as promising circulating biomarkers. This single-center study evaluated their diagnostic performance in patients with colorectal cancer and compared their utility with established tumor markers. Serum concentrations of PBEF/NAMPT, chemerin, and OPN were determined using a magnetic bead-based multiplex immunoassay (Luminex technology), whereas carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured by chemiluminescent microparticle immunoassay (CMIA). The study included 76 patients with colorectal cancer and 38 healthy, colonoscopy-negative controls. Differences between groups were assessed using the Mann–Whitney U, Kruskal–Wallis and post hoc tests, and diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Serum concentrations of PBEF/NAMPT and OPN were significantly higher in patients with CRC than in healthy controls, whereas chemerin did not differ significantly between groups. Among the investigated immunometabolic biomarkers, OPN demonstrated the highest diagnostic accuracy (AUC = 0.747), followed by PBEF/NAMPT (AUC = 0.624), whereas chemerin showed no significant diagnostic value (AUC = 0.559). Combining immunometabolic biomarkers with CEA yielded numerically higher AUC values than CEA alone, with the OPN + CEA panel reaching the highest diagnostic accuracy (AUC = 0.910), followed by the PBEF/NAMPT + CEA combination (AUC = 0.875); however, these increases did not reach statistical significance when formally compared with CEA alone. Among the evaluated immunometabolic biomarkers, OPN demonstrated the greatest diagnostic potential for colorectal cancer, and its combination with CEA warrants further investigation, although these findings should be considered exploratory given the limited sample size and the absence of external validation. Larger, multicenter studies using clinically relevant comparator groups are needed to establish the clinical utility of such multimarker strategies for the non-invasive diagnosis of CRC.
- Open Access
Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring
Background: Liquid biopsy using circulating tumor DNA (ctDNA) is rapidly reshaping gastrointestinal (GI) oncology. The highest-impact applications are molecular residual disease (mRD) detection after curative-intent therapy and early recognition of progression or resistance during systemic treatment. Methods: We performed a structured, clinically oriented narrative synthesis by using explicit search, eligibility, evidence prioritization, and clinical interpretation rules, integrating landmark prospective cohorts, randomized ctDNA-guided strategy trials where available, meta-analyses, key methodological research (e.g., pre-analytics, assay design, and clonal hematopoiesis (CH)/clonal hematopoiesis of indeterminate potential (CHIP)), and selected trial registries. Results: In resected colorectal cancer (CRC), postoperative ctDNA positivity is among the strongest known biomarkers of recurrence risk; large prospective studies demonstrate clear separation of disease-free survival (DFS)/overall survival (OS) between mRD+ and mRD− patients. In stage II colon cancer, randomized data (DYNAMIC) show that a ctDNA-guided strategy reduces adjuvant chemotherapy exposure without compromising long-term outcomes. In metastatic CRC, ctDNA supports early response monitoring and resistance tracking; ctDNA-selected anti-EGFR rechallenge provides a model of biomarker-driven actionability (CHRONOS). In gastroesophageal cancers, longitudinal ctDNA dynamics correlate with relapse risk and treatment efficacy, and in esophageal squamous cell carcinoma, ctDNA after neoadjuvant chemoradiotherapy informs residual disease risk and adjuvant stratification. In pancreatic ductal adenocarcinoma and hepatobiliary malignancies, sensitivity is constrained by low shedding and background cell-free DNA (cfDNA), yet ctDNA positivity remains clinically meaningful, and emerging data in resected extrahepatic cholangiocarcinoma (STAMP-linked analyses) show that ctDNA dynamics during adjuvant therapy predict recurrence. Conclusions: ctDNA is a clinically validated biomarker for mRD in CRC, whereas in other GI cancers, it remains a promising but methodologically heterogeneous tool whose clinical utility is tumor- and context-dependent. The next phase requires interventional trials demonstrating outcome improvement, harmonized sampling and reporting standards, and rigorous control of confounders (notably CH/CHIP).
Open AccessLiquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring
Background: Liquid biopsy using circulating tumor DNA (ctDNA) is rapidly reshaping gastrointestinal (GI) oncology. The highest-impact applications are molecular residual disease (mRD) detection after curative-intent therapy and early recognition of progression or resistance during systemic treatment. Methods: We performed a structured, clinically oriented narrative synthesis by using explicit search, eligibility, evidence prioritization, and clinical interpretation rules, integrating landmark prospective cohorts, randomized ctDNA-guided strategy trials where available, meta-analyses, key methodological research (e.g., pre-analytics, assay design, and clonal hematopoiesis (CH)/clonal hematopoiesis of indeterminate potential (CHIP)), and selected trial registries. Results: In resected colorectal cancer (CRC), postoperative ctDNA positivity is among the strongest known biomarkers of recurrence risk; large prospective studies demonstrate clear separation of disease-free survival (DFS)/overall survival (OS) between mRD+ and mRD− patients. In stage II colon cancer, randomized data (DYNAMIC) show that a ctDNA-guided strategy reduces adjuvant chemotherapy exposure without compromising long-term outcomes. In metastatic CRC, ctDNA supports early response monitoring and resistance tracking; ctDNA-selected anti-EGFR rechallenge provides a model of biomarker-driven actionability (CHRONOS). In gastroesophageal cancers, longitudinal ctDNA dynamics correlate with relapse risk and treatment efficacy, and in esophageal squamous cell carcinoma, ctDNA after neoadjuvant chemoradiotherapy informs residual disease risk and adjuvant stratification. In pancreatic ductal adenocarcinoma and hepatobiliary malignancies, sensitivity is constrained by low shedding and background cell-free DNA (cfDNA), yet ctDNA positivity remains clinically meaningful, and emerging data in resected extrahepatic cholangiocarcinoma (STAMP-linked analyses) show that ctDNA dynamics during adjuvant therapy predict recurrence. Conclusions: ctDNA is a clinically validated biomarker for mRD in CRC, whereas in other GI cancers, it remains a promising but methodologically heterogeneous tool whose clinical utility is tumor- and context-dependent. The next phase requires interventional trials demonstrating outcome improvement, harmonized sampling and reporting standards, and rigorous control of confounders (notably CH/CHIP).
- Open Access
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11601
Serum YKL-40, but Not Relaxin-2, Shows Diagnostic Utility as an Adjunct Biomarker in Colorectal Cancer
Despite the availability of conventional serum markers for colorectal cancer (CEA, CA 19-9), there remains a need for more sensitive and specific biomarkers, particularly for early-stage detection. This study evaluated the diagnostic usefulness of serum Relaxin-2 (RLN2) and Chitinase-3-like protein 1 (YKL-40) as potential adjunct markers in patients with CRC. Serum concentrations of all the proteins were measured using a multiplexing assay and CMIA and were subsequently compared using non-parametric statistical tests. The concentrations of YKL-40, CEA, and CA 19-9 were elevated in CRC patients relative to controls (p < 0.05), but not so for RLN2. The concentrations of YKL-40 were also significantly elevated in patients undergoing chemotherapy or preoperative radiotherapy referral. Kruskal–Wallis and post-hoc testing found that YKL-40 and CEA were associated with tumor progression, but RLN2 and CA 19-9 were increased primarily in advanced, metastatic disease. No statistically significant differences in marker levels were observed between cancer subtypes or between histologic grades. Performance analysis for diagnostic purposes showed YKL-40 was moderately sensitive (65%) but very specific (77.5%), and its AUC was 0.702, higher than CA 19-9 (AUC = 0.632) but lower than CEA (AUC = 0.869) (all p < 0.05). RLN2 did not reach statistical significance (AUC = 0.593, p = 0.09). Correlation analysis demonstrated the best correlation with disease stage for CEA and weaker positive correlations for YKL-40, CA 19-9, and RLN2. These findings suggest that YKL-40 may serve as a useful adjunct serum biomarker for CRC diagnosis, especially when combined with conventional markers such as CEA.
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11601
Open AccessSerum YKL-40, but Not Relaxin-2, Shows Diagnostic Utility as an Adjunct Biomarker in Colorectal Cancer
Despite the availability of conventional serum markers for colorectal cancer (CEA, CA 19-9), there remains a need for more sensitive and specific biomarkers, particularly for early-stage detection. This study evaluated the diagnostic usefulness of serum Relaxin-2 (RLN2) and Chitinase-3-like protein 1 (YKL-40) as potential adjunct markers in patients with CRC. Serum concentrations of all the proteins were measured using a multiplexing assay and CMIA and were subsequently compared using non-parametric statistical tests. The concentrations of YKL-40, CEA, and CA 19-9 were elevated in CRC patients relative to controls (p < 0.05), but not so for RLN2. The concentrations of YKL-40 were also significantly elevated in patients undergoing chemotherapy or preoperative radiotherapy referral. Kruskal–Wallis and post-hoc testing found that YKL-40 and CEA were associated with tumor progression, but RLN2 and CA 19-9 were increased primarily in advanced, metastatic disease. No statistically significant differences in marker levels were observed between cancer subtypes or between histologic grades. Performance analysis for diagnostic purposes showed YKL-40 was moderately sensitive (65%) but very specific (77.5%), and its AUC was 0.702, higher than CA 19-9 (AUC = 0.632) but lower than CEA (AUC = 0.869) (all p < 0.05). RLN2 did not reach statistical significance (AUC = 0.593, p = 0.09). Correlation analysis demonstrated the best correlation with disease stage for CEA and weaker positive correlations for YKL-40, CA 19-9, and RLN2. These findings suggest that YKL-40 may serve as a useful adjunct serum biomarker for CRC diagnosis, especially when combined with conventional markers such as CEA.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 7-12
Colostomy reversal after oncological resections versus non-oncological resections is not associated with worse postoperative outcomes – the results of the Polish Liquidation of Colostomy (LICO) study
Introduction: Colostomy reversal is a common surgical procedure following oncological and non-oncological resections. Colostomy reversal is performed in 60% in of non-oncological patients, and in only 40% of patients operated on for oncological reasons. Postoperative course as a possible reason for a lower colostomy reversal rate remains a controversial issue.Aim: To compare postoperative outcomes of colostomy reversal in patients with oncological versus non-oncological indications for colostomy creation.Materials and methods: The multicenter, prospective Liquidation of Colostomy (LICO) study was conducted in 20 surgical departments in Poland between October 2022 and December 2023. Patients were divided into two groups based on colostomy indication: oncological (Group 1) and non-oncological (Group 2). Primary outcomes were the length of hospital stay (LOS), postoperative complications, and 30-day reoperation rates.Results: Among 126 patients (46 in Group 1, 80 in Group 2), Group 1 patients were older (median 67 vs. 55.5 years, p<0.05) and had a higher prevalence of ischemic heart disease (32.6% vs. 10%, p = 0.002). Median LOS was 7 days for both groups (p = 0.656). Complication rates (34.8% in Group 1 vs. 43.8% in Group 2, p = 0.32) and reoperation rates (6.5% vs. 12.5%, p = 0.289) showed no significant differences. Intraoperative blood loss, operative times, and Clavien-Dindo complication grades were comparable between groups.Discussion: The results challenge the assumption that colostomy reversal after oncological resections carries higher risks. Comparable outcomes suggest perioperative care and patient selection are more critical than the underlying indication for colostomy.Conclusions: Colostomy reversal outcomes, including LOS, complications, and reoperations, were similar between oncological and non-oncological patients, supporting its safety in properly selected oncological cases without active disease.Significance of the study: This study provides evidence to guide clinical decision-making and refine guidelines, ultimately improving outcomes for patients undergoing colostomy reversal.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 7-12
Colostomy reversal after oncological resections versus non-oncological resections is not associated with worse postoperative outcomes – the results of the Polish Liquidation of Colostomy (LICO) study
Introduction: Colostomy reversal is a common surgical procedure following oncological and non-oncological resections. Colostomy reversal is performed in 60% in of non-oncological patients, and in only 40% of patients operated on for oncological reasons. Postoperative course as a possible reason for a lower colostomy reversal rate remains a controversial issue.Aim: To compare postoperative outcomes of colostomy reversal in patients with oncological versus non-oncological indications for colostomy creation.Materials and methods: The multicenter, prospective Liquidation of Colostomy (LICO) study was conducted in 20 surgical departments in Poland between October 2022 and December 2023. Patients were divided into two groups based on colostomy indication: oncological (Group 1) and non-oncological (Group 2). Primary outcomes were the length of hospital stay (LOS), postoperative complications, and 30-day reoperation rates.Results: Among 126 patients (46 in Group 1, 80 in Group 2), Group 1 patients were older (median 67 vs. 55.5 years, p<0.05) and had a higher prevalence of ischemic heart disease (32.6% vs. 10%, p = 0.002). Median LOS was 7 days for both groups (p = 0.656). Complication rates (34.8% in Group 1 vs. 43.8% in Group 2, p = 0.32) and reoperation rates (6.5% vs. 12.5%, p = 0.289) showed no significant differences. Intraoperative blood loss, operative times, and Clavien-Dindo complication grades were comparable between groups.Discussion: The results challenge the assumption that colostomy reversal after oncological resections carries higher risks. Comparable outcomes suggest perioperative care and patient selection are more critical than the underlying indication for colostomy.Conclusions: Colostomy reversal outcomes, including LOS, complications, and reoperations, were similar between oncological and non-oncological patients, supporting its safety in properly selected oncological cases without active disease.Significance of the study: This study provides evidence to guide clinical decision-making and refine guidelines, ultimately improving outcomes for patients undergoing colostomy reversal.
- Top Cited PapersOpen Access
- 21 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 1841
The Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis
Ovarian cancer is among the most lethal gynecologic malignancies, often diagnosed at advanced stages due to a lack of effective screening tools. Recent studies suggest that the platelet-to-lymphocyte ratio (PLR), an indicator of systemic inflammation, may serve as a potential biomarker for diagnosing and staging ovarian cancer. We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. We searched the PubMed/Medline, Scopus, Web of Science, and EMBASE databases. We pooled data using a random-effects model to assess the sensitivity, specificity, and diagnostic performance of PLR in ovarian cancer. The meta-analysis of 22 studies comprising 5740 participants showed significantly elevated platelet-to-lymphocyte ratio (PLR) values in ovarian cancer patients compared to healthy controls, with a mean difference of 46.84 (p < 0.001). Additionally, PLR demonstrated utility in distinguishing benign from malignant lesions and early-stage from advanced-stage ovarian cancer. While PLR shows potential as a cost-effective and accessible biomarker for ovarian cancer diagnosis and staging, its diagnostic accuracy remains moderate. Therefore, combining PLR with other diagnostic tools enhances clinical decision-making.
- 21 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 1841
Top Cited PapersOpen AccessThe Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis
Ovarian cancer is among the most lethal gynecologic malignancies, often diagnosed at advanced stages due to a lack of effective screening tools. Recent studies suggest that the platelet-to-lymphocyte ratio (PLR), an indicator of systemic inflammation, may serve as a potential biomarker for diagnosing and staging ovarian cancer. We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. We searched the PubMed/Medline, Scopus, Web of Science, and EMBASE databases. We pooled data using a random-effects model to assess the sensitivity, specificity, and diagnostic performance of PLR in ovarian cancer. The meta-analysis of 22 studies comprising 5740 participants showed significantly elevated platelet-to-lymphocyte ratio (PLR) values in ovarian cancer patients compared to healthy controls, with a mean difference of 46.84 (p < 0.001). Additionally, PLR demonstrated utility in distinguishing benign from malignant lesions and early-stage from advanced-stage ovarian cancer. While PLR shows potential as a cost-effective and accessible biomarker for ovarian cancer diagnosis and staging, its diagnostic accuracy remains moderate. Therefore, combining PLR with other diagnostic tools enhances clinical decision-making.
- Open Access
Can Ileostomy Reversal Be Safely Performed by Surgical Residents?
Background and Objectives: The growing number of colorectal cancer patients has highlighted the importance of surgical education in colorectal surgery. Despite the negative impact of the COVID-19 pandemic on surgical training, recent changes in the Polish surgical training program have increased the number of intestinal procedures required to be completed by residents. This study aims to assess the safety of ileostomy reversal procedures performed by surgical residents. Materials and Methods: A multicenter prospective cohort study, the LILEO study, was conducted from October 2022 until December 2023 across 20 Polish surgical departments. The study included 199 patients who underwent ileostomy reversal and were divided into two groups: 139 patients operated by specialist surgeons and 60 patients operated by surgical residents. The primary outcomes measured were postoperative complications, length of hospital stay (LOS), and 30-day reoperation rate. Secondary outcomes included the severity of perioperative complications assessed using the Clavien–Dindo classification and a focused analysis of loop ileostomy reversal outcomes. Results: The median LOS was significantly shorter in the resident group (5.5 days vs. 6 days, p < 0.05). Although the overall complication rate was lower in the resident group (21.7% vs. 33.1% in the specialist surgeon group), this difference was not statistically significant (p = 0.105). The 30-day reoperation rate was 3.3% in the resident group and 8.6% in the specialist surgeon group (p = 0.179). In terms of severity, minor complications (Clavien–Dindo grades 1 and 2) were more common in the specialist group (p < 0.05). The analysis of loop ileostomy reversals revealed no significant differences in postoperative outcomes between the two groups. Conclusions: Ileostomy reversal procedures performed by surgical residents under supervision are safe and feasible, with outcomes comparable to those performed only by specialist surgeons. These findings support ileostomy reversal as a valuable procedure for developing surgical residents’ skills and do not negatively affect postoperative outcomes.
Open AccessCan Ileostomy Reversal Be Safely Performed by Surgical Residents?
Background and Objectives: The growing number of colorectal cancer patients has highlighted the importance of surgical education in colorectal surgery. Despite the negative impact of the COVID-19 pandemic on surgical training, recent changes in the Polish surgical training program have increased the number of intestinal procedures required to be completed by residents. This study aims to assess the safety of ileostomy reversal procedures performed by surgical residents. Materials and Methods: A multicenter prospective cohort study, the LILEO study, was conducted from October 2022 until December 2023 across 20 Polish surgical departments. The study included 199 patients who underwent ileostomy reversal and were divided into two groups: 139 patients operated by specialist surgeons and 60 patients operated by surgical residents. The primary outcomes measured were postoperative complications, length of hospital stay (LOS), and 30-day reoperation rate. Secondary outcomes included the severity of perioperative complications assessed using the Clavien–Dindo classification and a focused analysis of loop ileostomy reversal outcomes. Results: The median LOS was significantly shorter in the resident group (5.5 days vs. 6 days, p < 0.05). Although the overall complication rate was lower in the resident group (21.7% vs. 33.1% in the specialist surgeon group), this difference was not statistically significant (p = 0.105). The 30-day reoperation rate was 3.3% in the resident group and 8.6% in the specialist surgeon group (p = 0.179). In terms of severity, minor complications (Clavien–Dindo grades 1 and 2) were more common in the specialist group (p < 0.05). The analysis of loop ileostomy reversals revealed no significant differences in postoperative outcomes between the two groups. Conclusions: Ileostomy reversal procedures performed by surgical residents under supervision are safe and feasible, with outcomes comparable to those performed only by specialist surgeons. These findings support ileostomy reversal as a valuable procedure for developing surgical residents’ skills and do not negatively affect postoperative outcomes.
- Open Access
- 31 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 934
Timing of Loop Ileostomy Closure Does Not Play a Pivotal Role in Terms of Complications—Results of the Liquidation of iLEOstomy (LILEO) Study
Loop ileostomy is commonly performed by colorectal and general surgeons to protect newly created large bowel anastomoses. The optimal timing for ileostomy closure remains debatable. Defining the timing associated with the best postoperative outcomes can significantly improve the clinical results for patients undergoing ileostomy closure. The LILEO study was a prospective multicenter cohort study conducted in Poland from October 2022 to December 2023. Full data analysis involved 159 patients from 19 surgical centers. Patients were categorized based on the timing of ileostomy reversal: early (6 months). Data on demographics, clinical characteristics, and perioperative outcomes were analyzed for each group separately and compared. No significant differences were observed in length of hospital stay (p = 0.22), overall postoperative complications (p = 0.43), or 30-day reoperation rates (p = 0.28) across the three groups. Additional analysis of Clavien–Dindo complication grades was performed and did not show significant differences in complication severity (p = 0.95), indicating that the timing of ileostomy closure does not significantly impact perioperative complications or hospital stay. Decisions on ileostomy reversal timing should be personalized and should consider individual clinical factors, including the type of adjuvant oncological treatment and the preventive measures performed for common postoperative complications.
- 31 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 934
Open AccessTiming of Loop Ileostomy Closure Does Not Play a Pivotal Role in Terms of Complications—Results of the Liquidation of iLEOstomy (LILEO) Study
Loop ileostomy is commonly performed by colorectal and general surgeons to protect newly created large bowel anastomoses. The optimal timing for ileostomy closure remains debatable. Defining the timing associated with the best postoperative outcomes can significantly improve the clinical results for patients undergoing ileostomy closure. The LILEO study was a prospective multicenter cohort study conducted in Poland from October 2022 to December 2023. Full data analysis involved 159 patients from 19 surgical centers. Patients were categorized based on the timing of ileostomy reversal: early (6 months). Data on demographics, clinical characteristics, and perioperative outcomes were analyzed for each group separately and compared. No significant differences were observed in length of hospital stay (p = 0.22), overall postoperative complications (p = 0.43), or 30-day reoperation rates (p = 0.28) across the three groups. Additional analysis of Clavien–Dindo complication grades was performed and did not show significant differences in complication severity (p = 0.95), indicating that the timing of ileostomy closure does not significantly impact perioperative complications or hospital stay. Decisions on ileostomy reversal timing should be personalized and should consider individual clinical factors, including the type of adjuvant oncological treatment and the preventive measures performed for common postoperative complications.
- Open Access
- 26 April 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (2) , 243-250
Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients
Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results. Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.
- 26 April 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (2) , 243-250
Open AccessStatins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients
Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results. Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.
- Open Access
Robotic versus Laparoscopic Liver Resections for Colorectal Metastases: A Systematic Review and Meta-Analysis
Colorectal cancer is the third most common cancer worldwide, and the liver is the most common localization of metastatic disease. The incidence of minimally invasive liver surgery is increasing, and robotic surgery (RLR) is believed to overcome some limitations of a laparoscopic approach (LRL). We performed a systematic review and meta-analysis of operative and short-term oncologic outcomes of the laparoscopic versus robotic-assisted liver resection for colorectal liver metastases. An online search of PubMed, Embase, Scopus, and the Cochrane databases was performed. Eight studies involving 3210 patients were considered eligible for the meta-analysis. In the LRL group, a higher conversion to open rate (12.4%) was observed compared to the RLR (6.7%; p = p = 0.76). Mortality in longer periods among LLR and RLR amounted to 18.2% vs. 8.0% for 1-year mortality (p = 0.07), 34.1% vs. 26.7% for 2-year mortality (p = 0.13), and 52.3% vs. 48.3% for 3-year mortality (p = 0.46). The length of hospital stay was 5.6 ± 2.5 vs. 5.8 ± 2.1 days, respectively (p = 0.47). There were no significant differences between the incidence of individual complications in the LRL and RLR groups (p = 0.78). Laparoscopic or robotic approaches for colorectal liver metastases are comparable in terms of safety and effectiveness. There are significant advantages to robotic surgery, although there is still no long-term evidence concerning overall survival, and the number of patients operated on using RLR remains small.
Open AccessRobotic versus Laparoscopic Liver Resections for Colorectal Metastases: A Systematic Review and Meta-Analysis
Colorectal cancer is the third most common cancer worldwide, and the liver is the most common localization of metastatic disease. The incidence of minimally invasive liver surgery is increasing, and robotic surgery (RLR) is believed to overcome some limitations of a laparoscopic approach (LRL). We performed a systematic review and meta-analysis of operative and short-term oncologic outcomes of the laparoscopic versus robotic-assisted liver resection for colorectal liver metastases. An online search of PubMed, Embase, Scopus, and the Cochrane databases was performed. Eight studies involving 3210 patients were considered eligible for the meta-analysis. In the LRL group, a higher conversion to open rate (12.4%) was observed compared to the RLR (6.7%; p = p = 0.76). Mortality in longer periods among LLR and RLR amounted to 18.2% vs. 8.0% for 1-year mortality (p = 0.07), 34.1% vs. 26.7% for 2-year mortality (p = 0.13), and 52.3% vs. 48.3% for 3-year mortality (p = 0.46). The length of hospital stay was 5.6 ± 2.5 vs. 5.8 ± 2.1 days, respectively (p = 0.47). There were no significant differences between the incidence of individual complications in the LRL and RLR groups (p = 0.78). Laparoscopic or robotic approaches for colorectal liver metastases are comparable in terms of safety and effectiveness. There are significant advantages to robotic surgery, although there is still no long-term evidence concerning overall survival, and the number of patients operated on using RLR remains small.